Integrin Activation Controls Metastasis in Human Breast Cancer
Overview
Authors
Affiliations
Metastasis is the primary cause of death in human breast cancer. Metastasis to bone, lungs, liver, and brain involves dissemination of breast cancer cells via the bloodstream and requires adhesion within the vasculature. Blood cell adhesion within the vasculature depends on integrins, a family of transmembrane adhesion receptors, and is regulated by integrin activation. Here we show that integrin alpha v beta 3 supports breast cancer cell attachment under blood flow conditions in an activation-dependent manner. Integrin alpha v beta 3 was found in two distinct functional states in human breast cancer cells. The activated, but not the nonactivated, state supported tumor cell arrest during blood flow through interaction with platelets. Importantly, activated alpha v beta 3 was expressed by freshly isolated metastatic human breast cancer cells and variants of the MDA-MB 435 human breast cancer cell line, derived from mammary fat pad tumors or distant metastases in severe combined immunodeficient mice. Expression of constitutively activated mutant alpha v beta 3(D723R), but not alpha v beta 3(WT), in MDA-MB 435 cells strongly promoted metastasis in the mouse model. Thus breast cancer cells can exhibit a platelet-interactive and metastatic phenotype that is controlled by the activation of integrin alpha v beta 3. Consequently, alterations within tumors that lead to the aberrant control of integrin activation are expected to adversely affect the course of human breast cancer.
A machine learning-based investigation of integrin expression patterns in cancer and metastasis.
Shadman H, Gomrok S, Litle C, Cheng Q, Jiang Y, Huang X Sci Rep. 2025; 15(1):5270.
PMID: 39939698 PMC: 11821851. DOI: 10.1038/s41598-025-89497-w.
Revolutionizing cancer treatment: an in-depth exploration of CAR-T cell therapies.
Kandav G, Chandel A Med Oncol. 2024; 41(11):275.
PMID: 39400611 DOI: 10.1007/s12032-024-02491-6.
Von Willebrand factor and hematogenous cancer metastasis under flow.
Xu W, Tan X, Li M, Xu H, Villegas J, Fu H Front Cell Dev Biol. 2024; 12:1435718.
PMID: 39282473 PMC: 11401050. DOI: 10.3389/fcell.2024.1435718.
Sidechain structure-activity relationships of cyclobutane-based small molecule αvβ3 antagonists.
Throup A, Zraikat M, Gordon A, Jafarinejad Soumehsaraei S, Haase K, Patterson L RSC Med Chem. 2024; .
PMID: 39281803 PMC: 11393731. DOI: 10.1039/d4md00306c.
Tang M, Zhang Z, Wang P, Zhao F, Miao L, Wang Y Acta Pharm Sin B. 2024; 14(8):3457-3475.
PMID: 39220884 PMC: 11365446. DOI: 10.1016/j.apsb.2024.04.034.